Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 53.41 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $5.023 million which beat the analyst consensus estimate of $4.520 million by 11.13 percent. This is a 46.06 percent increase over sales of $3.439 million the same period last year.